The review article analyzes the existing world experience in the use of interferons IFN-α and -γ as well as drugs based on them in clinical veterinary practice in cattle and pigs. The selection of literary sources was carried out on the basis of their relevance and the depth of the research (search retrospectiveness is 30 years). It has been established that IFNs are widely used in the prevention and treatment of both infectious and non-infectious diseases, which can be divided into 3 groups: viral infections, oncological diseases, bacterial and aseptic diseases. The use of IFNs is due to their antiviral activity and immunoregulatory effect. Thus, IFN-α exhibits antiviral activity and is the first line of nonspecific immune defense, an inducer of IFN-γ synthesis and the main coordinator of the body's successful response to a viral infection. At the same time, IFN-γ provides immunoregulatory, anti-inflammatory and mediated antibacterial action by stimulating the production of macrophages and participating in the differentiation of lymphocytes. Clinical efficacy is expressed in a decrease or cessation of the infectious process, a decrease in leukocytosis and neutrophilia, relief of acidotic syndrome, an increase in the body weight of animals and an improvement in the general clinical condition. Currently, IFN therapy is one of the most promising and constantly expanding areas of immunopharmacology and treatment of common respiratory, gastrointestinal, obstetric-gynecological diseases in farm animals.
The combination of immunomodulators and antibiotics in the treatment of animals with diseases of bacterial etiology is one of the effective strategies for animal therapy. The drug gentabiferon-B combines antibiotic gentamicin and species-specific (bovine) recombinant interferons -α and -γ. The study aimed to evaluate the effect of course application of gentabiferon-B on the cytogenetic stability of bone marrow cells of outbred mice after administering mitomycin C (MMC). The proportion of polychromatophilic erythrocytes in the bone marrow was assessed. There was no effect of gentabiferon-B on the frequency of polychromatophilic erythrocytes with micronuclei in both healthy animals and mice with MMC-induced cytogenetic instability. The course application of gentabiferon-B before the administration of MMC led to an increase in the proportion of polychromatophilic erythrocytes (46.03±2.61%) which was non-significantly different than the negative control group. The administration of MMC alone caused a decrease in the proportion of polychromatophilic erythrocytes to 33.33±1.83%. The antitoxic effect of gentabiferon-B led to an increase in the level of polychromatophilic erythrocytes by 38.1% compared to the group that received only MMC. Studies have shown that gentabiferon-B does not have mutagenic activity and anticlastogenic properties, however, it reduces the toxic effect of MMC. In conclusion, it is indicative that gentabiferon-B has antitoxic properties and can be safely used in animal therapy.
The experiment involved 10 rabbits with a live weight of 2.7-3.0 kg, divided into 2 groups. Group 1 (n=5) was the control one, with no administration of the drug to the animals. The animals of group 2 (n=5) were injected submastin in-tramuscularly at a dose of 0.1 ml/kg once daily within 3 days. A day after the last injection of the drug, diagnostic killing was performed. It has been found that after the course of therapy with the drug submastin, the animal meat does not change its chemical composition and retains its good quality as a result of the organoleptic and physicochemical assessment, and also possesses no adverse impact on the meat safety after animal slaughter.
The article presents data on the study of the effect of gentabiferon-B on the functional status of kidneys in white rat males with prolonged administration of the drug for 21 days. It was found that the administration of gentabiferon-B at doses of 1/50 and 1/20 LD50 did not have a significant effect on renal function in terms of spontaneous and induced diuresis, urea and creatinine concentrations, and no significant changes were revealed by pathomorphological examination. In rats, after a course of gentabiferon-B administration at a dose of 1/10 LD50, according to the above mentioned indicators, there were registered significant changes relative to the control group. However, all of them were reversible, which was confirmed by the results of studies 10 days after the drug withdrawal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.